Peptide LibraryHuman study PLS-00250
Clinical Trial in Patients With Barth Syndrome- 4TAZPower
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- Clinical Trial in Patients With Barth Syndrome- 4TAZPowerregistry entry · NCT07531251 (RECRUITING, no results posted, planned enrollment 48)
Design and participants
- Design
- Other design
- Population
- Patients with Barth syndrome. Eligibility criteria and age range are not stated in the record.
- Conditions
- Barth Syndrome
- Planned enrollment (registry)
- 48
- Enrolled
- Not reported
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
- Elamipretide (intervention) · elamipretide · Registry lists the interventions 'Elamipretide' and 'elamipretide hydrochloride'. · Not reported assigned
- Placebo (comparator) · Placebo listed as an intervention in the registry. · placebo · Not reported assigned
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- other: The record does not state the allocation method, masking or registered outcomes, although a placebo is listed.
- abstract only: Only stored registry fields are available. There is no publication, abstract or outcome description in the record.
- small or imprecise: Estimated enrollment is only 48 participants, which limits precision for any future results.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves function in Barth syndrome: not eligible (insufficient data) for “Muscle strength, exercise capacity and fatigue”
- Improves exercise capacity in primary mitochondrial myopathy: not eligible (wrong population) for “Six-minute walk distance and fatigue”
- Is safe for human administration: not eligible (insufficient data) for “Adverse events, including injection-site reactions, and discontinuations”
Where each value comes from
- arms: NCT NCT07531251, registry (interventions field) · extracted by AI (automated, not verified by a person)
- design: NCT NCT07531251, registry (study_type and phases fields) · extracted by AI (automated, not verified by a person)
- limitations: NCT NCT07531251, registry (status and has_results fields) · extracted by AI (automated, not verified by a person)
- participants: NCT NCT07531251, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
- population: NCT NCT07531251, registry (conditions field) · extracted by AI (automated, not verified by a person)
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).